Novo Nordisk

285.15 DKK

-0.78%

1,049 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

-0.78 %
+9.69 %
+19.51 %
-12.33 %
-9.25 %
-38.05 %
-49.87 %
+16.80 %
+22,803.61 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.27T DKK
Turnover
418.89M DKK
Revenue
309.06B
EBIT %
41.3 %
P/E
12.37
Dividend yield-%
4.1 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.8
2026

Interim report Q2'26

4.11
2026

Interim report Q3'26

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Forum discussions
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity...
Defensive victory. I am officially declaring the end of my Novo-bearishness here. Based on the opening rounds, Wegovy vs Foundayo looks to be a win for Denmark.
Novo Nordisk News Details Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US. Q1 2026 adjusted sales, excluding the 340B provision reversal, decreased by 4% at CER, driven...
Novo Nordisk’s results a pleasant surprise for a change — One drug rose above the rest Novo Nordisk is raising its guidance following a surprisingly strong first quarter. Tärkeimmät talousuutiset | Kauppalehti – 6 May 26 Novo Nordiskin tulos vaihteeksi iloinen yllätys – Yksi lääke...
Novo aims to shorten the “time-to-market” for new drugs by up to two-thirds using AI. AI is being utilized in areas such as analyzing research data and drafting documents. The company’s unit in India plays a central role in this development, where the focus has shifted from mass ...
Inderes Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in... Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial1 Participants...
Novo visibility again on CNBC: https://www.cnbc.com/2026/05/18/novo-nordisk-wegovy-pill-launch-eli-lilly-foundayo-weight-loss.html Key Points Novo Nordisk sees a “major opportunity” outside of the U.S. and says that telehealth partners could help grow the global market for weight...
Read more on our forum